Key result
This review summarizes the latest molecules evaluated as non-polio Enterovirus inhibitors and their structure-activity relationships to facilitate the design of future broad-spectrum drugs.
Why the study?
Despite the clinical need and widespread disease burden of non-polio Enteroviruses, no antiviral is currently marketed.
This review provides a comprehensive summary of recent non-polio Enterovirus inhibitors to aid in the development of broad-spectrum antiviral drugs.
Enterovirus (EV) is a genus that includes a large diversity of viruses spread around the world. They are the main cause of numerous diseases with seasonal clusters, like hand-foot-mouth disease (HFMD). A vaccine is marketed in China for the prevention of HFMD caused by EV-A71. Despite the need, no antiviral is marketed to date. Therefore, several compounds have been currently evaluated to inhibit non-polio Enterovirus (NPEV), namely direct antiviral agents and host target inhibitor. We propose to make a review of the latest molecules evaluated as NPEV inhibitors and to summarize structure-activity relationships between these inhibitors and their target. We provide access to all recent information on Enterovirus inhibitors, regardless of the species, to facilitate the design of future broad-spectrum drugs.
No takes yet. Share an insight, caveat, or question.
Roux et al. (2024) conducted a review in Non-polio Enterovirus (NPEV) infection. Non-polio Enterovirus (NPEV) inhibitors was evaluated. This review summarizes the latest molecules evaluated as non-polio Enterovirus inhibitors and their structure-activity relationships to facilitate the design of future broad-spectrum drugs.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: